Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Veliparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 6/20 | 1.00 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 1.00 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 1.00 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veliparib SCHEMBL29354914 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL30418660 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422318 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29843298 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL5511373 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422319 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368887 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368883 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368889 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29455770 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275434-B1 | AN EXTENDED RELEASE ORAL DOSAGE FORM | SANDOZ AG (CH) | 2020-08-26 | — | — | EP | claimed |
| CN-106432195-B | Method for preparing (R) -2- (2-methylpyrrolidine-2-yl) -1H-benzimidazole-4-formamide | 杭州民生药物研究院有限公司 | 2020-01-14 | — | — | CN | claimed |
| US-20190247371-A1 | METHODS FOR TREATING SMALL CELL LUNG CANCERS BY USING PHARMACEUTICAL COMPOSITIONS OR COMBINATIONS COMPRISING INDOLIZINO[6,7-B]INDOLE DERIVATIVES | ACADEMIA SINICA (TW) | 2019-08-15 | — | — | US | claimed |
| EP-3515437-A1 | METHODS FOR TREATING SMALL CELL LUNG CANCERS BY USING PHARMACEUTICAL COMPOSITIONS OR COMBINATIONS COMPRISING INDOLIZINO (6,7-B) INDOLE DERIVATIVES | Academia Sinica (TW) | 2019-07-31 | — | — | EP | claimed |
| WO-2018057712-A1 | METHODS FOR TREATING SMALL CELL LUNG CANCERS BY USING PHARMACEUTICAL COMPOSITIONS OR COMBINATIONS COMPRISING INDOLIZINO (6,7-B) INDOLE DERIVATIVES | ACADEMIA SINICA (TW) | 2018-03-29 | — | — | WO | claimed |
| EP-3275434-A1 | AN EXTENDED RELEASE ORAL DOSAGE FORM | SANDOZ AG (CH) | 2018-01-31 | — | — | EP | claimed |
| EP-2727921-B1 | 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 2 | ABBVIE IRELAND UNLIMITED CO (IE) | 2017-04-19 | — | — | EP | claimed |
| US-9580410-B2 | 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1 | ABBVIE INC. (US) | 2017-02-28 | — | — | US | claimed |
| EP-2722046-B1 | 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1 | ABBVIE IRELAND UNLIMITED CO (IE) | 2016-12-21 | — | — | EP | claimed |
| EP-2217603-B1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | ABBVIE BAHAMAS LTD (BS) | 2015-11-18 | — | — | EP | claimed |
| US-8013168-B2 | Veliparib crystal structure; an anticancer PARP inhibitor | ABBOTT LABORATORIES (US) | 2011-09-06 | — | — | US | claimed |
| EP-2217603-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | Abbott Laboratories (US) | 2010-08-18 | — | — | EP | claimed |
| EP-2212327-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | Abbott Laboratories (US) | 2010-08-04 | — | — | EP | claimed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | claimed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20090099245-A1 | 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | US | claimed |
| US-20090099246-A1 | 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | US | claimed |
| WO-2009049111-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | claimed |
| WO-2009049109-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | claimed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099245-A1 | 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | TPMT, MALT1, GOT2 | PARP1 739/4885PARP2 266/4885PARP3 1454/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-20190247371-A1 | METHODS FOR TREATING SMALL CELL LUNG CANCERS BY USING PHARMACEUTICAL COMPOSITIONS OR COMBINATIONS COMPRISING INDOLIZINO[6,7-B]INDOLE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RB1, INMT | PARP1 730/4885PARP2 664/4885PARP3 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.